Unraveling the Function of PAX3-FOXO1’s Activation Domain in Rhabdomyosarcoma |
Case Western Reserve University / Berkley Gryder, PhD |
'A' Award Grants |
2023 |
Ohio |
Genomic and nuclear organizational changes in chemotherapy-resistant rhabdomyosarcoma cells |
Ann & Robert H. Lurie Children’s Hospital of Chicago / Kyle MacQuarrie, MD/PhD |
'A' Award Grants |
2023 |
Illinois |
Empowering specificity of AML immunotherapies by HSC engineering |
Boston Children’s Hospital / Pietro Genovese |
Catalyst Grants |
2023 |
Massachusetts |
A Novel Adjunctive LAT-Activating CART (ALA-CART) Cell Platform for the Treatment of Acute Leukemia |
University of Colorado Denver_ Anschutz Medical Campus / Catherine Danis, PhD |
Young Investigator Grants |
2023 |
Colorado |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Creating an Infrastructure for Collaborative Clinical Research and Publication of Consensus Guidelines for RUNX1 Familial Platelet Disorder |
The Cleveland Clinic Foundation / Brittany Stewart, PhD |
RUNX1 Early Career Investigator Grants |
2023 |
Ohio |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Epigenetic therapies to concurrently target DIPG tumor cells and harness the immune system |
The Regents of the University of Michigan / Sriram Venneti, MD/PhD |
R Accelerated Award Grants |
2022 |
Michigan |
Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG |
The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD |
Reach Grants |
2022 |
Michigan |
Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia |
The Johns Hopkins University School of Medicine / Linda Resar, MD and Jian Jin, PhD |
Innovation Grants |
2022 |
Maryland |